HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma.

AbstractPURPOSE:
Vitamin D insufficiency is common in the United States, with low levels linked in some studies to higher cancer incidence, including non-Hodgkin's lymphoma (NHL). Recent data also suggest that vitamin D insufficiency is related to inferior prognosis in some cancers, although there are no data for NHL.
PATIENTS AND METHODS:
We tested the hypothesis that circulating 25-hydroxyvitamin D [25(OH)D] levels are predictive of event-free survival (EFS) and overall survival (OS) in a prospective cohort of 983 newly diagnosed patients with NHL. 25(OH)D and 1,25-dihydroxyvitamin D [1,25(OH)(2)D] levels were measured by liquid chromatography-tandem mass spectrometry.
RESULTS:
Mean age at diagnosis was 62 years (range, 19 to 94 years); 44% of patients had insufficient 25(OH)D levels (< 25 ng/mL) within 120 days of diagnosis. Median follow-up was 34.8 months; 404 events and 193 deaths (168 from lymphoma) occurred. After adjusting for known prognostic factors and treatment, 25(OH)D insufficient patients with diffuse large B-cell lymphoma (DLBCL) had inferior EFS (hazard ratio [HR], 1.41; 95% CI, 0.98 to 2.04) and OS (HR, 1.99; 95% CI, 1.27 to 3.13); 25(OH)D insufficient patients with T-cell lymphoma also had inferior EFS (HR, 1.94; 95% CI, 1.04 to 3.61) and OS (HR, 2.38; 95% CI, 1.04 to 5.41). There were no associations with EFS for the other NHL subtypes. Among patients with DLBCL and T-cell lymphoma, higher 1,25(OH)(2)D levels were associated with better EFS and OS, suggesting that any putative tumor 1-α-hydroxylase activity did not explain the 25(OH)D associations.
CONCLUSION:
25(OH)D insufficiency was associated with inferior EFS and OS in DLBCL and T-cell lymphoma. Whether normalizing vitamin D levels in these patients improves outcomes will require testing in future trials.
AuthorsMatthew T Drake, Matthew J Maurer, Brian K Link, Thomas M Habermann, Stephen M Ansell, Ivana N Micallef, Jennifer L Kelly, William R Macon, Grzegorz S Nowakowski, David J Inwards, Patrick B Johnston, Ravinder J Singh, Cristine Allmer, Susan L Slager, George J Weiner, Thomas E Witzig, James R Cerhan
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 28 Issue 27 Pg. 4191-8 (Sep 20 2010) ISSN: 1527-7755 [Electronic] United States
PMID20713849 (Publication Type: Journal Article, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers
  • Vitamin D
  • 1,25-dihydroxyvitamin D
  • 25-hydroxyvitamin D
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers (blood)
  • Chi-Square Distribution
  • Chromatography, Liquid
  • Disease-Free Survival
  • Female
  • Humans
  • Iowa
  • Kaplan-Meier Estimate
  • Lymphoma, Non-Hodgkin (blood, complications, mortality, therapy)
  • Male
  • Middle Aged
  • Minnesota
  • Proportional Hazards Models
  • Prospective Studies
  • Risk Assessment
  • Risk Factors
  • Tandem Mass Spectrometry
  • Time Factors
  • Treatment Outcome
  • Vitamin D (analogs & derivatives, blood)
  • Vitamin D Deficiency (blood, complications, mortality)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: